证券代码：301103 证券简称：何氏眼科 公告编号：2023-020 辽宁何氏眼科医院集团股份有限公司 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 15 日（星期一）15：00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码， 进入问题征集专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注 的问题进行回答。欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码，扫码自动匹配移动端） 特此公告。 辽宁何氏眼科医院集团股份有限公司董事会 2023 年 4 月 25 日 1 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）于 2023 年 5 月 18 日（星期四）下午 15：00-17：00 在全景网举行 2022 年度网上业绩说明会， 本次业绩说明会将采用网络远程的方式举行，投资者可登录全景网"投资者关系 ...

辽宁何氏眼科医院集团股份有限公司 2022 年第三季度报告 证券代码：301103 证券简称：何氏眼科 公告编号：2022-042 辽宁何氏眼科医院集团股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 303,429,504.07 | 8.32% | 771,544,366.56 | 3.60% | | 归属于上市公司股东的 | 23,922,584.93 | -22.52% | 65,734,604.74 | -26.85% | | 净利润（元） | | | | | | 归属于上市公司股东的 扣 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 468,114,862.49, a slight increase of 0.75% compared to the same period last year[22]. - Net profit attributable to shareholders decreased by 29.12% to CNY 41,812,019.81, while the net profit after deducting non-recurring gains and losses fell by 31.99% to CNY 39,553,335.53[22]. - The net cash flow from operating activities was CNY 88,495,866.42, down 21.71% year-on-year[22]. - Basic and diluted earnings per share dropped by 41.25% to CNY 0.2928[22]. - Total assets increased by 80.57% to CNY 2,566,174,763.08 compared to the end of the previous year[22]. - Net assets attributable to shareholders rose by 107.96% to CNY 2,182,842,197.40[22]. - Operating costs increased by 4.26% to approximately CNY 276.87 million, primarily due to the expansion of hospital scale and increased personnel and depreciation expenses[72]. - Sales expenses rose by 20.44% to approximately CNY 65.42 million, attributed to new personnel and advertising marketing costs[72]. - Management expenses increased by 26.34% to approximately CNY 68.56 million, mainly due to increased labor costs from new personnel[72]. - The company reported a net cash inflow from financing activities of approximately CNY 1.07 billion, a significant increase of 4,122.35% due to funds raised from the company's IPO[72]. Market Expansion and Strategy - The company is expanding its market presence in key regions such as Beijing, Shanghai, and the Greater Bay Area, aiming for a nationwide strategic footprint[44]. - The company is implementing a "1+N" national layout strategy, which aims to establish one eye hospital to support multiple optical clinics, enhancing patient flow and service integration[45]. - The company is actively constructing the Hainan Boao He Eye Hospital, which will leverage special policies for international medical research and treatment[51]. - The company is exploring potential acquisitions to enhance its service capabilities and market reach[190]. - The company plans to expand its market presence and invest in new product development to drive future growth[196]. Operational Developments - The company has initiated the construction of 2 new hospital projects and 5 optical clinic projects in Liaoning Province, expanding its service capacity[45]. - The company has established a unified procurement model to enhance bargaining power and ensure the quality of medical supplies and equipment[41]. - The company has established a comprehensive talent training system for ophthalmology professionals, including the "Jingcai Plan" and "Excellence Talent Plan," aimed at continuously supplying high-quality ophthalmologists and management teams[59]. - The company has established partnerships with several universities to train master's and doctoral students, enhancing its talent pool[58]. - The company has a high-quality medical team with 50 national-level society members and 68 provincial-level society members, contributing to its strong service capabilities[57]. Research and Development - The company has conducted over 50 clinical trial projects for various ophthalmic drugs, including 10 projects in the first half of 2022 alone[54]. - Research and development expenses decreased by 46.62% to approximately CNY 308.93 thousand, due to reduced costs associated with stability observation studies[72]. - The company is focusing on research and development of new products to meet evolving market demands[200]. - The company has introduced advanced technologies such as cataract phacoemulsification and vitreous cutting, and collaborates with leading biotech firms for genetic testing in ophthalmology[50]. Social Responsibility and Community Engagement - The company is committed to social responsibility, contributing to rural revitalization and health initiatives through innovative technology and partnerships[109]. - The company is involved in a public welfare project in four provinces, focusing on ophthalmology and poverty alleviation[109]. - The company launched a public welfare project for eye health management, reaching over 1.25 million viewers during its online campaign[68]. - The company reached over 1.25 million online viewers during the "National Eye Day" event, promoting eye health education through various media platforms[110]. - The company conducted online and offline eye health education, reaching a total of 300,000 participants during the first half of 2022[111]. Regulatory and Compliance - The company is subject to strict regulatory oversight in the healthcare sector, which may impact future business development[93]. - The company is committed to transparency and compliance with regulatory requirements, as evidenced by its detailed disclosures in the semi-annual report[150]. - The company has not engaged in any entrusted financial management or derivative investments during the reporting period[87]. Shareholder Information - The company reported no significant related party transactions that contributed to over 10% of the total profit during the reporting period[137]. - The total number of common stock shareholders at the end of the reporting period is 22,795[155]. - The largest shareholder, He Wei, holds 19.19% of the shares, totaling 30,327,379 shares, with an increase of 6,998,626 shares during the reporting period[155]. - The company’s shareholding structure includes 76.20% held by limited sale condition shares and 23.80% held by unrestricted sale condition shares[145]. - The company has a plan for the release of restricted shares, with significant portions set to be released in March 2023 and September 2025[151].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 241,753,611.42, representing a 14.94% increase compared to CNY 210,327,528.92 in the same period last year[3] - The net profit attributable to shareholders decreased by 6.66% to CNY 26,088,609.26 from CNY 27,950,361.13 year-on-year[3] - Total operating costs for Q1 2022 were CNY 202,966,878.11, up 18.76% from CNY 170,860,125.80 in the previous year[23] - Net profit for Q1 2022 was CNY 26,088,609.26, a decrease of 6.68% from CNY 27,950,361.13 in Q1 2021[24] - The total comprehensive income for the first quarter was CNY 26,088,609.26, a decrease from CNY 27,950,361.13 in the previous period, reflecting a decline of approximately 6.7%[26] - Basic and diluted earnings per share for the quarter were CNY 0.2865, down from CNY 0.3069, indicating a decrease of about 7.5%[26] Cash Flow - The net cash flow from operating activities increased by 40.50% to CNY 63,683,424.40, up from CNY 45,327,342.71 in the previous year[3] - Cash inflow from operating activities was CNY 266,992,813.72, compared to CNY 228,458,882.66 in the previous period, representing an increase of approximately 16.9%[27] - Cash flow from financing activities showed a significant increase, with a net cash inflow of CNY 1,176,715,004.05 compared to a cash outflow of CNY 14,420,977.10 in the previous period[29] - The company reported a cash outflow of CNY 203,309,389.32 from operating activities, which was higher than the previous period's outflow of CNY 183,131,539.95[28] - The company has shown a strong increase in cash flow from financing activities, indicating potential for future investments and growth[29] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,644,806,040.59, an increase of 86.11% from CNY 1,421,131,071.37 at the end of the previous year[3] - Total liabilities for Q1 2022 amounted to CNY 404,751,959.34, compared to CNY 371,476,863.60 in the previous year[21] - The company's total equity reached CNY 2,240,054,081.25 in Q1 2022, up from CNY 1,049,654,207.77 in Q1 2021[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,613[12] - The largest shareholder, He Wei, holds 19.19% of the shares, amounting to 23,328,753 shares[12] - The company completed its initial public offering, issuing 30.5 million shares, increasing its registered capital from RMB 91,058,824 to RMB 121,558,824[17] - The total number of shares after the IPO is 121,558,824[17] - The company has a total of 92,632,517 restricted shares, with various release dates[16] - The top ten shareholders collectively hold significant stakes, with the top three holding a combined 38.38%[12] - The company has a diverse shareholder base, including both individual and institutional investors[12] Research and Development - Research and development expenses decreased by 38.10% to CNY 16,510.00, attributed to the stabilization study of a product approved in October 2021[8] - Research and development expenses for Q1 2022 were CNY 165,166.61, a decrease from CNY 266,841.99 in Q1 2021[23] Operational Insights - The company experienced a 40.37% increase in accounts payable, reaching CNY 14,433,460.00, due to increased inventory in response to pandemic-related concerns[8] - The net profit decline was influenced by the opening of new subsidiaries, which incurred fixed costs before achieving significant revenue[9] - The company’s cash and cash equivalents increased by 175.67% compared to the previous year, reflecting expanded operational scale and increased cash from stock issuance[8] - The company is focused on expanding its market presence and enhancing shareholder value through strategic initiatives[17]

Financial Performance - The company's operating revenue for 2021 was CNY 962,451,382.32, representing a 14.79% increase compared to CNY 838,473,305.39 in 2020[5]. - The net profit attributable to shareholders decreased by 13.84% to CNY 86,364,346.62 in 2021 from CNY 100,235,908.91 in 2020[5]. - The net cash flow from operating activities increased by 25.84% to CNY 213,605,810.89 in 2021, up from CNY 169,743,992.06 in 2020[5]. - The total assets of the company at the end of 2021 were CNY 1,421,131,071.37, an increase of 28.68% from CNY 1,104,382,442.90 at the end of 2020[5]. - The basic earnings per share decreased by 13.84% to CNY 0.9484 in 2021 from CNY 1.1008 in 2020[5]. - The company's operating profit for 2021 was CNY 129.46 million, a decrease of 9.58% year-on-year, while the net profit attributable to shareholders was CNY 86.36 million, down 13.84%[62]. - The total operating revenue for 2021 was ¥962,451,382.32, representing a year-on-year increase of 14.79% compared to ¥838,473,305.39 in 2020[74]. - The medical business accounted for ¥958,685,936.01, or 99.61% of total revenue, with a growth of 14.85% from ¥834,723,218.89 in the previous year[75]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2021, representing a year-on-year growth of 15%[164]. - The company reported a net profit margin of 12% for the year, reflecting improved operational efficiency[164]. Dividend and Capital Management - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares to all shareholders, based on a total of 121,558,824 shares[4]. - The company will increase its capital reserve by converting 3 shares for every 10 shares held by shareholders[4]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors, highlighting the importance of understanding investment risks[4]. - The company implements a stable profit distribution policy, prioritizing cash dividends when conditions are met, with a minimum cash distribution of 10% of the annual distributable profit[197]. - In cases of significant investment plans or cash expenditures, the company may opt for stock dividends instead of cash[195]. - The company aims for a minimum cash dividend ratio of 80% during profit distribution if it is in a mature stage without major expenditures[199]. - The company's profit distribution policy is designed to consider the opinions of independent directors and public investors[194]. Risk Management - The company has a comprehensive risk management strategy outlined in the report, addressing potential operational risks and countermeasures[4]. - The company recognizes the risk of regulatory changes in the healthcare industry that could impact its operations and will actively monitor policy trends to adapt its business model accordingly[113]. - The ongoing global pandemic poses significant operational risks, with potential adverse effects on the company's performance if the situation does not improve[117]. - The company has implemented measures to minimize the impact of the pandemic while ensuring employee health and maintaining operations[118]. Market Position and Growth Strategy - The company is positioned in a rapidly growing ophthalmology service market, with an annual growth rate of 23.70% in revenue from 2009 to 2019[31]. - The company aims to expand its operations in economically developed regions with high population density, focusing on areas like Beijing-Tianjin-Hebei, Yangtze River Delta, and Guangdong-Hong Kong-Macau Greater Bay Area[101]. - The company is expanding its business from Liaoning to regions centered around Beijing, Shanghai, Shenzhen, and Chengdu, aiming to enhance its brand image through high-quality medical services and social welfare activities[115]. - The company is exploring international expansion opportunities, particularly in Southeast Asia, to diversify its revenue streams[149]. - The company is actively investing in advanced eye care technologies, including gene and stem cell treatments, and has established partnerships with leading biotechnology firms[46]. - The company has expanded its market presence by establishing new eye care facilities in key regions, including Beijing and Chongqing, laying a solid foundation for further expansion in the Chengdu-Chongqing and Beijing-Tianjin-Hebei areas[63]. Human Resources and Training - The company has a comprehensive human resource training system, with 50 national-level society members and numerous awards in professional skill competitions[50]. - The company collaborates with several universities to train master's and doctoral students, ensuring a steady supply of qualified medical professionals[51]. - The company has established a specialized training system for optometry and nursing professionals, ensuring a continuous output of skilled personnel[52]. - The company has established a high-quality talent training mechanism, collaborating with Dalian Medical University since 2001 to cultivate over 100 master's and doctoral students in various medical fields[192]. - The company has a total of 646 marketing and operations personnel, and 1,597 medical technology and service personnel[186]. - The company has implemented a dynamic salary adjustment mechanism based on employee competency evaluations, aiming to maximize employee motivation[188]. - The company has established a performance evaluation system based on a balanced scorecard methodology, incorporating metrics such as workload, medical quality, research innovation, and talent development[189]. Research and Development - The company successfully developed a 0.01% concentration atropine sulfate for myopia prevention, approved for sale in November 2021[65]. - The company completed 11 clinical trial projects in 2021 and has 13 ongoing research projects, emphasizing its commitment to clinical research[66]. - Research and development investments increased by 25%, totaling 50 million RMB, focusing on innovative eye treatment solutions[149]. - The company is investing 50 million RMB in research and development to innovate new medical technologies over the next two years[167]. - The company has established partnerships with two leading medical technology firms to enhance its service offerings and improve patient care[162]. Governance and Compliance - The company has established a robust internal control system to enhance governance and risk management, continuously improving its operational standards[126]. - The board of directors consists of 14 members, including 5 independent directors, and has conducted 17 meetings, effectively fulfilling its responsibilities[124]. - The supervisory board, comprising 3 members, has held 16 meetings, ensuring compliance with regulatory requirements[125]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[130]. - The company has a complete and independent business system for providing specialized ophthalmic diagnosis and treatment services, ensuring no competition or unfair transactions with its controlling shareholders[134]. - The company’s governance practices are in compliance with regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange[178]. Social Responsibility and Community Engagement - The company has actively engaged in social responsibility initiatives, including blindness prevention projects, and has been recognized for its contributions to public welfare[61]. - The company hosted significant academic events, including the Fourth International Genomics Conference on Ophthalmology, enhancing its academic brand and international influence[60]. - The company has hosted the fourth "China-Africa Eye Health Development Forum," showcasing its commitment to international collaboration in eye health[71].